Table V.
Antibody response to SARS-CoV-2 vaccine in predominant antibody deficiency patients by underlying immunophenotype
| Variable | Anti-spike antibody <100 U/mL (n = 25) |
Anti-spike antibody ≥100 U/mL (n = 37) |
P |
|---|---|---|---|
| Native immunoglobulin levels, mg/dL (mean) | |||
| IgG | 443 | 678 | <.01 |
| IgA | 45 | 171 | <.01 |
| IgM | 60 | 103 | .03 |
| IgG1 | 311 | 392 | .07 |
| IgG2 | 146 | 182 | .36 |
| IgG3 | 32 | 34 | .93 |
| IgG4 | 13 | 16 | .19 |
| Missing, n | (3-16) | (7-12) | |
| IgG antibody levels (mean) | |||
| Streptococcus pneumoniae (% >1.3 μg/mL) | 47 | 56 | .29 |
| Haemophilus influenzae, mg/L | 0.3 | 1.6 | <.01 |
| Tetanus, IU/mL | 0.98 | 1.4 | .42 |
| Diphtheria, IU/mL | 0.28 | 0.25 | .85 |
| Missing, n | (10-13) | (7-16) | |
| Flow cytometry (mean absolute count of cells/μL) | |||
| CD3+ | 986 | 1,287 | .04 |
| CD4+ | 559 | 810 | .02 |
| CD8+ | 356 | 416 | .3 |
| CD3–CD16+56+ | 190 | 200 | .71 |
| CD4+CD45RA+ | 234 | 348 | .05 |
| CD4+CD45RO+ | 309 | 393 | .37 |
| CD8+CD45RA+ | 179 | 240 | .41 |
| CD8+CD45RO+ | 145 | 134 | .71 |
| CD19+ | 129 | 256 | <.01 |
| CD19+CD27+ | 32 | 46 | .09 |
| CD19+CD27+IgM/IgD– | 4 | 12 | <.01 |
| CD19+CD27+IgM/IgD+ | 26 | 33 | .26 |
| Missing, n | (5-9) | (7-11) | |
| Severity markers | |||
| <20% CD4+CD45RA+ (% CD4+) | |||
| Odds ratio | Reference | 1 (0.16-6.1) | .64 |
| Missing (n = 14) | |||
| <5% CD19+CD27+ (% CD19+) | |||
| Odds ratio | Reference | 9.7 (1.9-49.9) | <.01 |
| Missing (n = 18) | |||
| <10% CD19+CD27+ (% CD19+) | |||
| Odds ratio | Reference | 2.3 (0.6-9) | .22 |
| Missing (n = 18) | |||
| <2% CD19+CD27+IgM/IgD– (% CD19+) | |||
| Odds ratio | Reference | 11 (2-60) | <.01 |
| Missing (n = 18) |